The results showed that the vaccine significantly reduced the proportion of MDSCs in both the spleen and the TME, and significantly increased the CD8/MDSC ratio, suggesting that the recombinant MUC1-MBP vaccine reversed immunosuppression by reducing MDSCs and thus controlled tumor growth. This evidence concerns the gene CD8A and neoplasm.